CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab - Niehr, Franziska; Weichert, Wilko; Stenzinger, Albrecht (BioMed Central, 2015)
Aus: Journal of Translational Medicine, 13 (2015), Nr. 106. pp. 1-13. ISSN 1479-5876